Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €1.51 EUR
Change Today -0.007 / -0.46%
Volume 0.0
NLZB On Other Exchanges
Symbol
Exchange
NLZB is not on other exchanges.
As of 5:06 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

neurometrix inc (NLZB) Snapshot

Open
€1.51
Previous Close
€1.52
Day High
€1.52
Day Low
€1.48
52 Week High
07/8/14 - €2.21
52 Week Low
09/23/14 - €1.18
Market Cap
12.3M
Average Volume 10 Days
120.0
EPS TTM
--
Shares Outstanding
8.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROMETRIX INC (NLZB)

Related News

No related news articles were found.

neurometrix inc (NLZB) Related Businessweek News

No Related Businessweek News Found

neurometrix inc (NLZB) Details

NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with carpal tunnel syndrome, lumbosacral disc disease, spinal stenosis, and diabetes. The company focuses on the diagnosis and treatment of neurological complications of diabetes. Its marketed products include SENSUS pain therapy device, a transcutaneous electrical nerve stimulator used for chronic and intractable pain, such as painful diabetic neuropathy; NC-stat DPNCheck, a device used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy (DPN); and ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies and invasive electromyography procedures for the assessment of carpal tunnel syndrome, low back and leg pain, and DPN, as well as consumables and accessories. The company distributes its products through its direct sales force and independent sales representatives to physicians, clinics, hospitals, managed care organizations, retail health businesses, and independent distributors consisting of primary care, internal medicine, orthopedic and hand surgeons, pain medicine physicians, neurologists, physical medicine and rehabilitation, physicians, and neurosurgeons, as well as endocrinology and podiatry markets primarily in the United States, Europe, Asia, and the Middle East. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.

32 Employees
Last Reported Date: 02/25/15
Founded in 1996

neurometrix inc (NLZB) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $414.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $300.4K
Senior Vice President and General Manager of ...
Total Annual Compensation: $150.1K
Compensation as of Fiscal Year 2014.

neurometrix inc (NLZB) Key Developments

NeuroMetrix Inc. Auditor Raises 'Going Concern' Doubt

NeuroMetrix Inc. filed its 10-K on Feb 25, 2015 for the period ending Dec 31, 2014. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

NeuroMetrix Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

NeuroMetrix Inc. announced unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenues of $1,409,629 compared to $1,402,152 a year ago. Loss from operations was $2,406,129 compared to $1,377,288 a year ago. Net loss was $2,909,200 compared to $3,703,628 a year ago. Net loss per common share applicable to common stockholders, basic and diluted was $0.36 compared to $0.87 a year ago. For the full year, the company reported revenues of $5,512,764 compared to $5,278,806 a year ago. Loss from operations was $8,770,049 compared to $7,358,840 a year ago. Net loss was $7,766,222 compared to $8,019,137 a year ago. Net loss per common share applicable to common stockholders, basic and diluted was $1.54 compared to $3.07 a year ago.

NeuroMetrix Inc. to Report Q4, 2014 Results on Feb 12, 2015

NeuroMetrix Inc. announced that they will report Q4, 2014 results at 9:00 AM, Eastern Standard Time on Feb 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NLZB:GR €1.51 EUR -0.007

NLZB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Natus Medical Inc $39.13 USD +1.05
View Industry Companies
 

Industry Analysis

NLZB

Industry Average

Valuation NLZB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROMETRIX INC, please visit www.neurometrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.